CMN Weekly (14 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 14, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Allogene Therapeutics
General information
Main focus: Allogeneic CAR-T cell therapies
Company stage: Clinical
Diseases: Non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), acute myeloid leukaemia (AML), renal cell carcinoma (RCC), small cell lung cancer (SCLC)
Genome editing tool: TALEN
Funding stage: Public (NASDAQ:ALLO)
Location: San Francisco, CA, USA
Website: http://allogene.com/
Pipeline: https://www.allogene.com/pipeline
Partners: Cellectis, Servier, Notch Therapeutics, SpringWorks Therapeutics, Pfizer
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Allogene is developing a pipeline ofoff-the-shelf CAR-T cell therapy candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
